FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2957005990> ?p ?o ?g. }

• W2957005990 endingPage "528" @default.
• W2957005990 startingPage "523" @default.
• W2957005990 abstract "Objective: To evaluate the therapeutic efficacy and safety of immunosuppressive therapy (IST) combined with recombinant human thrombopoietin (rhTPO) for severe aplastic anemia (SAA) in pediatric patients. Method: A retrospective case-control study was conducted and the clinical data of 45 pediatric patients with de novo SAA admitted to the Anemia Diagnosis and Treatment Center of Chinese Academy of Medical Sciences & Blood Disease Hospital during the period from December 2009 to December 2014 were analyzed. Among them, 15 patients were treated with the regimen of IST together with rhTPO and 30 patients were given IST treatment only. The variation characteristics of the peripheral blood routine as well as the transfusion of blood products was dynamically observed, and the therapeutic efficacy was assessed respectively after 3, 6 and 12 months after the treatment. In the meantime, adverse effects related to rhTPO application were recorded. Thereafter, the statistics of the two groups were compared by non-parametric rank sum test. Result: Among 45 pediatric patients, there were 26 male and 19 female, and the median age was 11 years (6-14). The number of patients received good hematological response(complete remission (CR) plus good partial response (GPR)) in the combinatory group versus vs. the IST group was 6 vs. 3 patients (χ(2)=3.906, P=0.048) at the 3rd month, 7 vs. 7 patients (χ(2)=1.568, P=0.210) at the 6th month, and 13 vs. 14 patients (χ(2)=6.667, P=0.01) at the 12th month respectively. For those achieved good hematological response at the 3rd month, the amount of platelets transfusion and red blood cells transfusion of the combined group were both less than that of the IST group during the period from the 10th to the 12th weeks (platelets transfusion: 1.4 U vs. 2.9 U, t=-3.523, P=0.002; red blood cells transfusion: 0.8 U vs. 2.6 U, t=-2.392, P=0.026). No serious adverse effect related to rhTPO application was observed in the IST combined with rhTPO group. Conclusion: Application of rhTPO can improve the short-term therapeutic efficacy of IST for pediatric SAA, alleviate transfusion dependence, and has a good safety profile.目的： 评价联合应用免疫抑制治疗(IST)和重组人血小板生成素(rhTPO)对儿童重型再生障碍性贫血(SAA)的效果和安全性。 方法： 回顾性病例对照研究，分析2009年12月至2014年12月中国医学科学院血液病医院贫血诊疗中心收治的45例SAA患儿资料，其中接受IST联合rhTPO方案者15例，单纯IST方案者30例，动态观察治疗后3、6、12个月的外周血常规变化和血制品输注情况并评价疗效，记录应用rhTPO患儿的不良反应，采用非参数秩和检验法对比两组资料。 结果： 45例患儿中男26例，女19例，中位诊断年龄11(10～13)岁，rhTPO联合IST组和IST组在3、6、12个月时获得良好血液学反应[完全缓解(CR)＋良好部分治疗反应(GPR)]的例数分别为6、7、13例和3、7、14例(χ(2)＝3.906、1.568、6.667, P＝0.048、0.210、0.010)。3个月时有效者，rhTPO联合IST组第10～12周血小板和红细胞的输注量均较IST组少(血小板1.4 U比2.9 U, t＝－3.523，P＝0.002；红细胞0.8 U比2.6 U，t＝－2.392，P＝0.026)，应用rhTPO患儿未发生相关严重不良反应。 结论： 应用rhTPO可以提高SAA患儿IST治疗的近期疗效，减轻输血依赖，其安全性较好。." @default.
• W2957005990 created "2019-07-23" @default.
• W2957005990 creator A5007764521 @default.
• W2957005990 creator A5009364448 @default.
• W2957005990 creator A5013745043 @default.
• W2957005990 creator A5014701419 @default.
• W2957005990 creator A5021391037 @default.
• W2957005990 creator A5026699304 @default.
• W2957005990 creator A5040134858 @default.
• W2957005990 creator A5047230741 @default.
• W2957005990 creator A5049857586 @default.
• W2957005990 creator A5061110102 @default.
• W2957005990 creator A5063604601 @default.
• W2957005990 creator A5083433874 @default.
• W2957005990 creator A5085384428 @default.
• W2957005990 creator A5087468984 @default.
• W2957005990 creator A5090749715 @default.
• W2957005990 date "2017-07-02" @default.
• W2957005990 modified "2023-09-23" @default.
• W2957005990 title "[Evaluation of efficacy of immunosuppressive therapy plus recombinant human thrombopoietin for children with severe aplastic anemia]." @default.
• W2957005990 doi "https://doi.org/10.3760/cma.j.issn.0578-1310.2017.07.011" @default.
• W2957005990 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28728262" @default.
• W2957005990 hasPublicationYear "2017" @default.
• W2957005990 type Work @default.
• W2957005990 sameAs 2957005990 @default.
• W2957005990 citedByCount "0" @default.
• W2957005990 crossrefType "journal-article" @default.
• W2957005990 hasAuthorship W2957005990A5007764521 @default.
• W2957005990 hasAuthorship W2957005990A5009364448 @default.
• W2957005990 hasAuthorship W2957005990A5013745043 @default.
• W2957005990 hasAuthorship W2957005990A5014701419 @default.
• W2957005990 hasAuthorship W2957005990A5021391037 @default.
• W2957005990 hasAuthorship W2957005990A5026699304 @default.
• W2957005990 hasAuthorship W2957005990A5040134858 @default.
• W2957005990 hasAuthorship W2957005990A5047230741 @default.
• W2957005990 hasAuthorship W2957005990A5049857586 @default.
• W2957005990 hasAuthorship W2957005990A5061110102 @default.
• W2957005990 hasAuthorship W2957005990A5063604601 @default.
• W2957005990 hasAuthorship W2957005990A5083433874 @default.
• W2957005990 hasAuthorship W2957005990A5085384428 @default.
• W2957005990 hasAuthorship W2957005990A5087468984 @default.
• W2957005990 hasAuthorship W2957005990A5090749715 @default.
• W2957005990 hasConcept C126322002 @default.
• W2957005990 hasConcept C141071460 @default.
• W2957005990 hasConcept C187212893 @default.
• W2957005990 hasConcept C197934379 @default.
• W2957005990 hasConcept C2778248108 @default.
• W2957005990 hasConcept C2780007613 @default.
• W2957005990 hasConcept C2781413609 @default.
• W2957005990 hasConcept C2781440808 @default.
• W2957005990 hasConcept C71924100 @default.
• W2957005990 hasConcept C90924648 @default.
• W2957005990 hasConceptScore W2957005990C126322002 @default.
• W2957005990 hasConceptScore W2957005990C141071460 @default.
• W2957005990 hasConceptScore W2957005990C187212893 @default.
• W2957005990 hasConceptScore W2957005990C197934379 @default.
• W2957005990 hasConceptScore W2957005990C2778248108 @default.
• W2957005990 hasConceptScore W2957005990C2780007613 @default.
• W2957005990 hasConceptScore W2957005990C2781413609 @default.
• W2957005990 hasConceptScore W2957005990C2781440808 @default.
• W2957005990 hasConceptScore W2957005990C71924100 @default.
• W2957005990 hasConceptScore W2957005990C90924648 @default.
• W2957005990 hasIssue "7" @default.
• W2957005990 hasLocation W29570059901 @default.
• W2957005990 hasOpenAccess W2957005990 @default.
• W2957005990 hasPrimaryLocation W29570059901 @default.
• W2957005990 hasRelatedWork W2003938723 @default.
• W2957005990 hasRelatedWork W2019517015 @default.
• W2957005990 hasRelatedWork W2118496982 @default.
• W2957005990 hasRelatedWork W2135977549 @default.
• W2957005990 hasRelatedWork W2342084165 @default.
• W2957005990 hasRelatedWork W2403511365 @default.
• W2957005990 hasRelatedWork W2439875401 @default.
• W2957005990 hasRelatedWork W2901330354 @default.
• W2957005990 hasRelatedWork W3203700472 @default.
• W2957005990 hasRelatedWork W2525756941 @default.
• W2957005990 hasVolume "55" @default.
• W2957005990 isParatext "false" @default.
• W2957005990 isRetracted "false" @default.
• W2957005990 magId "2957005990" @default.
• W2957005990 workType "article" @default.